Assuntos
Anticoagulantes/uso terapêutico , Produtos Biológicos/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Anticoagulantes/efeitos adversos , Produtos Biológicos/efeitos adversos , Ensaios Clínicos Fase III como Assunto , Qualidade de Produtos para o Consumidor , Aprovação de Drogas , Europa (Continente) , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Guias de Prática Clínica como Assunto , Medição de Risco , Terminologia como Assunto , Estados Unidos , United States Food and Drug AdministrationAssuntos
Anticoagulantes/administração & dosagem , Suplementos Nutricionais , Idoso , Instituições de Assistência Ambulatorial , Fibrilação Atrial/tratamento farmacológico , Interações Medicamentosas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Educação de Pacientes como Assunto , Preparações de Plantas/administração & dosagem , Inquéritos e Questionários , Varfarina/administração & dosagemRESUMO
In large part, antimicrobial drug discovery is driven by the breadth and quality of both potential drug targets and available chemical libraries to screen. Traditionally, targets have been few in number and have been limited to those with known function, from which biochemical assays could be implemented into drug screens. Iterations of this same basic approach, applied to a few biochemically-defined targets have identified a limited set of novel antibiotics and even fewer antifungal agents. Indeed, in the last 50 years less than 30 antimicrobial targets have been exploited commercially. Within infectious disease, the industry was driven largely by chemistry-based approaches, simply making new analogs to existing drugs to overcome the growing problem of drug resistance. Elitra Pharmaceutical s approach has been to enable true functional genomics on a genome-wide scale. Elitra s vision has been to identify all of the essential genes directly in the key pathogenic organisms. Having moved rapidly towards the completion of this goal, we are now faced with the enviable challenge of prioritizing enormous target sets and developing novel sensitive screens for those best suited as definitive drug targets. These highly sensitive, cell-based screening paradigms enable re-screening of even well screened chemical libraries to reveal new chemical entities displaying novel modes of action against new targets. In parallel, we have also begun to shift the paradigm from screening targets singly, towards genome-wide approaches to drug screening.
Assuntos
Anti-Infecciosos/farmacologia , Desenho de Fármacos , Genoma Bacteriano , Genoma Fúngico , Indústria Farmacêutica/métodos , Resistência Microbiana a Medicamentos/genética , Genes Essenciais/efeitos dos fármacos , Genes Essenciais/genética , Saccharomyces cerevisiae/genéticaRESUMO
In Saccharomyces cerevisiae, more than 80% of the approximately 6200 predicted genes are nonessential, implying that the genome is buffered from the phenotypic consequences of genetic perturbation. To evaluate function, we developed a method for systematic construction of double mutants, termed synthetic genetic array (SGA) analysis, in which a query mutation is crossed to an array of approximately 4700 deletion mutants. Inviable double-mutant meiotic progeny identify functional relationships between genes. SGA analysis of genes with roles in cytoskeletal organization (BNI1, ARP2, ARC40, BIM1), DNA synthesis and repair (SGS1, RAD27), or uncharacterized functions (BBC1, NBP2) generated a network of 291 interactions among 204 genes. Systematic application of this approach should produce a global map of gene function.
Assuntos
Proteínas do Citoesqueleto , Deleção de Genes , Genes Fúngicos/fisiologia , Técnicas Genéticas , Proteínas dos Microfilamentos , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/fisiologia , Proteínas de Transporte/genética , Proteínas de Transporte/fisiologia , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/fisiologia , Polaridade Celular , Biologia Computacional , Cruzamentos Genéticos , Citoesqueleto/fisiologia , DNA Helicases/genética , DNA Helicases/fisiologia , Reparo do DNA , DNA Fúngico/biossíntese , Bases de Dados Genéticas , Endodesoxirribonucleases/genética , Endodesoxirribonucleases/fisiologia , Endonucleases Flap , Proteínas Fúngicas/genética , Proteínas Fúngicas/fisiologia , Genes Essenciais , Marcadores Genéticos , Genoma Fúngico , Proteínas dos Microtúbulos/genética , Proteínas dos Microtúbulos/fisiologia , Mitose , RecQ Helicases , Recombinação Genética , Robótica , Saccharomyces cerevisiae/crescimento & desenvolvimento , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/fisiologiaRESUMO
The E4orf4 protein of human adenovirus induces p53-independent apoptosis, a process that may promote cell death and viral spread. When expressed alone, E4orf4 kills transformed cells but not normal human cells. The only clear target of E4orf4 in mammalian cells is the Balpha (B55) subunit of protein phosphatase 2A (PP2A), a member of one of three classes of regulatory B subunits. Here we report the effects of E4orf4 in Saccharomyces cerevisiae, which encodes two PP2A regulatory B subunits, CDC55 and RTS1, that share homology with mammalian B and B' subunits, respectively. E4orf4 expression was found to be toxic in yeast, resulting in the accumulation of cells in G2/M phase that failed to grow upon removal of E4orf4. E4orf4-expressing yeast also displayed an elongated cell morphology similar to cdc55 deletion strains. E4orf4 required CDC55 to elicit its effect, whereas RTS1 was dispensable. The recruitment of the PP2A holoenzyme by E4orf4 was entirely dependent on Cdc55. These studies indicate that E4orf4-induced apoptosis in mammalian cells and cell death in yeast require functional interactions with B-type subunits of PP2A. However, some inhibition of growth by E4orf4 was observed in the cdc55 strain and with an E4orf4 mutant that fails to interact with Cdc55, indicating that E4orf4 may possess a second Cdc55-independent function affecting cell growth.
Assuntos
Adenoviridae/genética , Proteínas de Ciclo Celular/metabolismo , Genes p53 , Fosfoproteínas Fosfatases/metabolismo , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/enzimologia , Saccharomyces cerevisiae/metabolismo , Fatores de Transcrição , Proteínas Virais/metabolismo , Proteínas Virais/toxicidade , Apoptose , Fatores de Transcrição Hélice-Alça-Hélice Básicos , Western Blotting , Divisão Celular , Linhagem Celular Transformada , Citometria de Fluxo , Proteínas Fúngicas/metabolismo , Galactose/farmacologia , Glucose/farmacologia , Humanos , Mitose , Fosforilação , Plasmídeos/metabolismo , Mutação Puntual , Testes de Precipitina , Ligação Proteica , Proteína Fosfatase 2 , Proteínas Repressoras/metabolismo , Fatores de TempoRESUMO
Saccharomyces cerevisiae can accumulate iron through the uptake of siderophore-iron. Siderophore-iron uptake can occur through the reduction of the complex and the subsequent uptake of iron by the high affinity iron transporter Fet3p/Ftr1p. Alternatively, specific siderophore transporters can take up the siderophore-iron complex. The pathogenic fungus Candida albicans can also take up siderophore-iron. Here we identify a C. albicans siderophore transporter, CaArn1p, and characterize its activity. CaARN1 is transcriptionally regulated in response to iron. Through expression studies in S. cerevisiae strains lacking endogenous siderophore transporters, we demonstrate that CaArn1p specifically mediates the uptake of ferrichrome-iron. Iron-ferrichrome and gallium-ferrichrome, but not desferri-ferrichrome, could competitively inhibit the uptake of iron from ferrichrome. Uptake of siderophore-iron resulting from expression of CaARN1 under the control of the MET25-promoter in S. cerevisiae was independent of the iron status of the cells and of Aft1p, the iron-sensing transcription factor. These studies demonstrate that the expression of CaArn1p is both necessary and sufficient for the nonreductive uptake of ferrichrome-iron and suggests that the transporter may be the only required component of the siderophore uptake system that is regulated by iron and Aft1p.
Assuntos
Candida albicans/química , Candida albicans/metabolismo , Proteínas de Transporte/química , Proteínas de Transporte/fisiologia , Proteínas de Transporte de Cátions , Ferricromo/metabolismo , Proteínas Fúngicas , Saccharomyces cerevisiae/química , Saccharomyces cerevisiae/metabolismo , Sequência de Aminoácidos , Transporte Biológico , Northern Blotting , Western Blotting , Proteínas de Transporte/biossíntese , Relação Dose-Resposta a Droga , Ferro/metabolismo , Ferro/farmacocinética , Ferro/farmacologia , Cinética , Metionina/metabolismo , Dados de Sequência Molecular , Plasmídeos/metabolismo , Regiões Promotoras Genéticas , Homologia de Sequência de Aminoácidos , Sideróforos/farmacocinéticaAssuntos
Anticoagulantes/efeitos adversos , Anticoagulantes/farmacocinética , Coeficiente Internacional Normatizado , Varfarina/efeitos adversos , Varfarina/farmacocinética , Anticoagulantes/antagonistas & inibidores , Hemorragia/induzido quimicamente , Hemorragia/tratamento farmacológico , Humanos , Projetos de Pesquisa/normas , Vitamina K/uso terapêutico , Varfarina/antagonistas & inibidoresRESUMO
The bipolar budding pattern of a/alpha Saccharomyces cerevisiae cells appears to depend on persistent spatial markers in the cell cortex at the two poles of the cell. Previous analysis of mutants with specific defects in bipolar budding identified BUD8 and BUD9 as potentially encoding components of the markers at the poles distal and proximal to the birth scar, respectively. Further genetic analysis reported here supports this hypothesis. Mutants deleted for BUD8 or BUD9 grow normally but bud exclusively from the proximal and distal poles, respectively, and the double-mutant phenotype suggests that the bipolar budding pathway has been totally disabled. Moreover, overexpression of these genes can cause either an increased bias for budding at the distal (BUD8) or proximal (BUD9) pole or a randomization of bud position, depending on the level of expression. The structures and localizations of Bud8p and Bud9p are also consistent with their postulated roles as cortical markers. Both proteins appear to be integral membrane proteins of the plasma membrane, and they have very similar overall structures, with long N-terminal domains that are both N- and O-glycosylated followed by a pair of putative transmembrane domains surrounding a short hydrophilic domain that is presumably cytoplasmic. The putative transmembrane and cytoplasmic domains of the two proteins are very similar in sequence. When Bud8p and Bud9p were localized by immunofluorescence and tagging with GFP, each protein was found predominantly in the expected location, with Bud8p at presumptive bud sites, bud tips, and the distal poles of daughter cells and Bud9p at the necks of large-budded cells and the proximal poles of daughter cells. Bud8p localized approximately normally in several mutants in which daughter cells are competent to form their first buds at the distal pole, but it was not detected in a bni1 mutant, in which such distal-pole budding is lost. Surprisingly, Bud8p localization to the presumptive bud site and bud tip also depends on actin but is independent of the septins.
Assuntos
Polaridade Celular/fisiologia , Proteínas Fúngicas/metabolismo , Glicoproteínas de Membrana , Proteínas de Membrana/metabolismo , Saccharomyces cerevisiae/fisiologia , Actinas/metabolismo , Sequência de Aminoácidos , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Fracionamento Celular , Proteínas Fúngicas/química , Proteínas Fúngicas/genética , Genes Reporter , Immunoblotting , Proteínas de Membrana/genética , Microscopia de Fluorescência , Dados de Sequência Molecular , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Saccharomyces cerevisiae/efeitos dos fármacos , Proteínas de Saccharomyces cerevisiae/química , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Alinhamento de Sequência , Tiazóis/farmacologia , TiazolidinasAssuntos
Fibrinolíticos/uso terapêutico , Próteses Valvulares Cardíacas , Coeficiente Internacional Normatizado , Avaliação de Resultados em Cuidados de Saúde , Terapia Trombolítica/normas , Trombose/prevenção & controle , Atenção à Saúde , Saúde Global , Humanos , Guias de Prática Clínica como AssuntoAssuntos
Anticoagulantes , Administração Oral , Anticoagulantes/farmacocinética , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Fibrilação Atrial/prevenção & controle , Cumarínicos/farmacologia , Cumarínicos/uso terapêutico , Interações Medicamentosas , Alimentos , Próteses Valvulares Cardíacas , Humanos , Infarto do Miocárdio/tratamento farmacológico , Tromboembolia/prevenção & controle , Trombose Venosa/prevenção & controle , Varfarina/farmacologia , Varfarina/uso terapêuticoAssuntos
Anticoagulantes/uso terapêutico , Administração Oral , Fatores Etários , Idoso , Anticoagulantes/administração & dosagem , Anticoagulantes/efeitos adversos , Anticoagulantes/farmacocinética , Síndrome Antifosfolipídica , Testes de Coagulação Sanguínea , Feminino , Hemorragia/induzido quimicamente , Humanos , Coeficiente Internacional Normatizado , Modelos Teóricos , Gravidez , Fatores de RiscoRESUMO
1. Permanent therapy with oral anticoagulants offers the most consistent protection in patients with mechanical heart valves. 2. Antiplatelet agents alone do not consistently protect patients with mechanical prosthetic heart valves, including patients in sinus rhythm with St. Jude Medical valves in the aortic position. 3. Levels of oral anticoagulants that prolong the INR to 2.0 to 3.0 appear satisfactory for patients with St. Jude Medical bileaflet and Medtronic-Hall tilting disk mechanical valves in the aortic position, provided they are in sinus rhythm and the left atrium is not enlarged. Presumably, this is also true for the CarboMedics bileaflet valve, based on the observation of no clinically important difference in the rate of systemic embolism with this valve and the St. Jude Medical bileaflet valve. 4. Levels of oral anticoagulants that prolong the INR to 2.5 to 3.5 are satisfactory for tilting disk valves and bileaflet prosthetic valves in the mitral position. 5. Experience in patients with caged ball valves who had prothrombin time ratios reported in terms of the INR is sparse, because few such valves have been inserted in recent years. The number of surviving patients with caged ball valves continues to decrease. It has been suggested that the most advantageous level of the INR in patients with caged ball or caged disk valves should be as high as 4.0 to 4.9. However, others have shown a high rate of major hemorrhage with an INR that is even somewhat lower, 3.0-4.5. The problem is self-limited, however, because few such valves are being inserted. 6. In patients with mechanical heart valves, aspirin, in addition to oral anticoagulants, has been shown to diminish the frequency of thromboemboli. The risk of bleeding is somewhat increased if the INR is 2.0 to 3.0 or 2.5 to 3.5. However, if the INR is 3.0 to 4.5, the risk of bleeding becomes excessive with aspirin. There are no investigations in which aspirin 80 mg/d in combination with oral anticoagulants was evaluated. 7. Data are insufficient to recommend dipyridamole over low doses of aspirin in combination with warfarin. Whether dipyridamole plus aspirin is more effective than aspirin alone when used with warfarin is undetermined. 8. Patients with bioprosthetic valves in the mitral position as well as patients with bioprosthetic valves in the aortic position may be at risk for thromboemboli during the first 3 months after operation. 9. Among patients with bioprosthetic valves in the mitral position, oral anticoagulants at an INR of 2.0 to 2.3 were as effective as an INR of 2.5 to 4.0 and were associated with fewer bleeding complications during the first 3 months after operation.10. Aspirin may reduce the long-term frequency of thromboembolism in patients with bioprosthetic valves.
Assuntos
Bioprótese , Fibrinolíticos/uso terapêutico , Próteses Valvulares Cardíacas , Administração Oral , Adulto , Idoso , Anticoagulantes/uso terapêutico , Aspirina/uso terapêutico , Criança , Dipiridamol/uso terapêutico , HumanosRESUMO
OBJECTIVE: To compare the dosing requirements and international normalized ratios (INRs) associated with two bioequivalent crystalline warfarin sodium products in patients with chronic atrial fibrillation. METHODS: A multicenter, single-blind (prescriber), randomized, crossover evaluation of Apothecon warfarin and DuPont warfarin (Coumadin) was conducted in consenting adults with chronic or paroxysmal atrial fibrillation who had been receiving DuPont warfarin chronically for the prevention of thromboembolism. Patients were randomly assigned to initially either continue DuPont warfarin or receive Apothecon warfarin for four weeks, with weekly evaluation of dosage and INR changes, safety, and efficacy. Subsequently, patients crossed over and received the other product for four weeks. RESULTS: There were 113 patients randomized to receive study treatment. Neither the propensity for a dosage change or an INR change nor the magnitude of a dosage change or INR change appeared related to a particular warfarin product (NS for each variable after each study period). After four weeks of treatment, the same number of patients (n = 7) experienced a > or = 20% change in warfarin dosage from the respective baseline with each product. The number of patients with INRs outside the desired protocol range after four weeks of treatment was similar for both groups (< 1.8, n = 9 for both products, or > 3.2, n = 9 for DuPont, n = 10 for Apothecon). No major hemorrhagic or thromboemoblic events occurred. CONCLUSIONS: The results of this study show that Apothecon warfarin and DuPont warfarin provide equivalent anticoagulation in patients with chronic or paroxysmal atrial fibrillation.
Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Varfarina/uso terapêutico , Idoso , Anticoagulantes/administração & dosagem , Anticoagulantes/efeitos adversos , Doença Crônica , Estudos Cross-Over , Feminino , Humanos , Masculino , Estudos Prospectivos , Resultado do Tratamento , Varfarina/administração & dosagem , Varfarina/efeitos adversosRESUMO
BACKGROUND: The American College of Chest Physicians addressed the dilemma of identifying optimal therapy for venous thromboembolism (VTE) prophylaxis and published their Fourth Consensus Conference on Antithrombotic Therapy in 1995, with recommendations for prophylactic therapy. Despite these recommendations, appropriate VTE prophylactic therapy is underused. OBJECTIVES: To examine routine practices in the prevention of VTE in high-risk surgical patients and to determine the extent of adoption of grade A prophylactic therapies as recommended by the American College of Chest Physicians. METHODS: Retrospective medical record review in 10 teaching or community-based hospitals located in the United States. Medical charts of 1907 patients were randomly selected for review from the population of patients who underwent high-risk major abdominal surgery, total hip replacement, hip fracture repair, or total knee replacement between January 1, 1996, and February 28, 1997. RESULTS: Of 1907 patients, VTE prophylaxis was used in 89.3%; use was 93.7% in each of the 3 orthopedic surgery groups and 75.2% in the high-risk major abdominal surgery group. The percentage of patients receiving grade A therapy was highest in the hip replacement group (84.3%) vs. the other groups (knee replacement, 75.9%; hip fracture repair, 45.2%; abdominal surgery, 50.3%). CONCLUSIONS: The use of grade A prophylaxis was related to the type of surgery, with the highest use seen in total hip replacement and the lowest in hip fracture repair. One in 4 patients who underwent high-risk major abdominal surgeries failed to receive any form of VTE prophylaxis. Publication of consensus statements alone may be insufficient to ensure the incorporation of important new clinical information into routine practice.
Assuntos
Anticoagulantes/uso terapêutico , Procedimentos Ortopédicos/efeitos adversos , Guias de Prática Clínica como Assunto/normas , Embolia Pulmonar/prevenção & controle , Pneumologia/normas , Veias Pulmonares/efeitos dos fármacos , Adulto , Idoso , Conferências de Consenso como Assunto , Enoxaparina/uso terapêutico , Humanos , Pessoa de Meia-Idade , Embolia Pulmonar/etiologia , Estudos Retrospectivos , Resultado do Tratamento , Estados Unidos , Varfarina/uso terapêuticoRESUMO
beta-1,6-Glucan is an essential fungal-specific component of the Saccharomyces cerevisiae cell wall that interconnects all other wall components into a lattice. Considerable biochemical and genetic effort has been directed at the identification and characterization of the steps involved in its biosynthesis. Structural studies show that the polymer plays a central role in wall structure, attaching mannoproteins via their glycosylphosphatidylinositol (GPI) glycan remnant to beta-1,3-glucan and chitin. Genetic approaches have identified genes that upon disruption result in beta-1,6-glucan defects of varying severity, often with reduced growth or lethality. These gene products have been localized throughout the secretory pathway and at the cell surface, suggesting a possible biosynthetic route. Current structural and genetic data have therefore allowed the development of models to predict biosynthetic events. Based on knowledge of beta-1,3-glucan and chitin synthesis, it is likely that the bulk of beta-1,6-glucan polymer synthesis occurs at the cell surface, but requires key prior intracellular events. However, the activity of most of the identified gene products remain unknown, making it unclear to what extent and how directly they contribute to the synthesis of this polymer. With the recent availability of new tools, reagents and methods (including genomics), the field is poised for a convergence of biochemical and genetic methods to identify and characterize the biochemical steps in the synthesis of this polymer.
Assuntos
Glucanos/biossíntese , Saccharomyces cerevisiae/metabolismo , beta-Glucanas , Parede Celular/química , Citoplasma/metabolismo , Retículo Endoplasmático/metabolismo , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Glucanos/química , Glicosilfosfatidilinositóis/química , Glicosilfosfatidilinositóis/metabolismo , Complexo de Golgi/metabolismoRESUMO
The genome of Saccharomyces cerevisiae contains five genes that encode type II transmembrane proteins with significant amino acid similarity to the alpha-1,3-mannosyltransferase Mnn1p. The roles of the three genes most closely related to MNN1 were examined in mutants carrying single and multiple combinations of the disrupted genes. Paper chromatographic analysis of [2-3H]mannose-labeled O-linked oligosaccharides released by beta-elimination showed that the MNT2 (YGL257c) and MNT3 (YIL014w) genes in combination with MNN1 have overlapping roles in the addition of the fourth and fifth alpha-1,3-linked mannose residues to form Man4 and Man5 oligosaccharides whereas MNT4 (YNR059w) does not appear to be required for O-glycan synthesis.
Assuntos
Manosiltransferases/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/enzimologia , Sequência de Aminoácidos , Genes Fúngicos , Manose/metabolismo , Manosiltransferases/genética , Glicoproteínas de Membrana/genética , Dados de Sequência Molecular , Família Multigênica , Mutação , Oligossacarídeos/biossíntese , Oligossacarídeos/química , Saccharomyces cerevisiae/genética , Homologia de Sequência de AminoácidosRESUMO
The functions of many open reading frames (ORFs) identified in genome-sequencing projects are unknown. New, whole-genome approaches are required to systematically determine their function. A total of 6925 Saccharomyces cerevisiae strains were constructed, by a high-throughput strategy, each with a precise deletion of one of 2026 ORFs (more than one-third of the ORFs in the genome). Of the deleted ORFs, 17 percent were essential for viability in rich medium. The phenotypes of more than 500 deletion strains were assayed in parallel. Of the deletion strains, 40 percent showed quantitative growth defects in either rich or minimal medium.